Owner Glenmark Pharmaceuticals S.A.

Inventors Lazarides, Elias; Bernard, Mark; Woods, Catherine

Agent Davies Collison Cave

Pub. Number AU-B-2006315037

PCT Pub. Number WO2007/056858

Priority 60/738,303 18.11.05 US

Filing date 17 November 2006

Wipo publication date 24 May 2007

Acceptance publication date 6 September 2012

C12N 15/13 Mutation or genetic engineering - Immunoglobulins

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/00 Drugs for skeletal disorders

A61P 35/00 Antineoplastic agents

A61P 37/02 Drugs for immunological or allergic disorders

C07K 14/705 Peptides having more than 20 amino acids

C07K 14/78 Peptides having more than 20 amino acids

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/63 Mutation or genetic engineering - Introduction of foreign genetic material using vectors

C12P 21/08 Preparation of peptides or proteins - Monoclonal antibodies

G01N 33/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

G01N 33/543 Investigating or analysing materials by specific methods not covered by groups - with an insoluble carrier for immobilising immunochemicals

G01N 33/566 Investigating or analysing materials by specific methods not covered by groups - using specific carrier or receptor proteins as ligand binding reagent